MESO

Mesoblast Ltd ADR

14.29

Nov 04 • 3:59 PM ET -0.48 (-3.25%)

14.70

Aftermarket • 6:03 PM ET +0.41 (2.87%)

Healthcare Biotechnology Australia Small NASD

Peers: VCEL SNDX INCY CAPR LCTX PLUR IOVA CRSP BCDA BRTX

| Held by: IBB APIE QQQS IBBQ BIB

Scroll to Statements

Index	-
Market Cap	1.86B
Enterprise Value	1.88B
Income	-57.63M
Sales	120.57M
Book/sh	4.38
Cash/sh	0.79
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	108
IPO	Jan 18, 2006

P/E	-
Forward P/E	55.78
PEG	-
P/S	15.42
P/B	3.26
P/C	18.07
P/FCF	-
EV/EBITDA	-
EV/Sales	15.62
Quick Ratio	2.09
Current Ratio	2.43
Debt/Eq	0.22
LT Debt/Eq	0.20
Option/Short	Yes / Yes

EPS (ttm)	-0.45
EPS next Y	0.26
EPS next Q	-0.08
EPS this Y	64.45%
EPS next Y	262.31%
EPS next 5Y	-
EPS past 3/5Y	24.72% 22.09%
Sales past 3/5Y	152.90% 74.52%
EPS Y/Y TTM	47.33%
Sales Y/Y TTM	600.89%
EPS Q/Q	12.33%
Sales Q/Q	-5.36%
Earnings	Aug 26 AMC
EPS/Sales Surpr.	-23.98% -6.61%

Insider Own	-
Insider Trans	-
Inst Own	3.02%
Inst Trans	-20.32%
ROA	-7.40%
ROE	-9.89%
ROIC	-8.45%
Gross Margin	84.10%
Oper. Margin	-42.63%
Profit Margin	-47.80%
SMA20	4.83%
SMA50	-3.35%
SMA200	-7.02%
Trades

Shs Outstand	130.11M
Shs Float	128.29M
Short Float	2.55%
Short Ratio	13.80
Short Interest	3.27M
52W High	21.50 -33.53%
52W Low	11.89 20.19%
Volatility	3.55% 3.20%
ATR (14)	0.68
RSI (14)	51.59
Beta	2.22
Rel Volume	1.49
Avg Volume	236.85K
Volume	353,111

Perf Week	6.72%
Perf Month	5.00%
Perf Quarter	-8.51%
Perf Half Y	-9.61%
Perf YTD	-20.79%
Perf Year	-8.34%
Perf 3Y	453.88%
Perf 5Y	11.82%
Perf 10Y	60.57%
Recom	1.00
Target Price	30.21
Prev Close	14.77
Price	14.29
Change %	-3.25%

Consensus

Strong Buy

Avg. Price Target

$30.21

Implied Upside

+111.4%

Analysts7incl. previous ratings

Rating Distribution4 Buy · 2 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 25, 2025	Upgrade	JJefferies	Hold → Buy
Jul 18, 2025	Downgrade	JJefferies	Buy → Hold
Dec 23, 2024	Downgrade	JJefferies	Buy → Hold
Sep 24, 2024	Upgrade	MMaxim Group	Hold → Buy	$12	-16.0%
Aug 29, 2024	Upgrade	JJefferies	Hold → Buy
Jul 23, 2024	Upgrade	PPiper Sandler	Neutral → Overweight	$4 → $11	-23.0%
Aug 31, 2023	Upgrade	JJefferies	Hold → Buy
Aug 07, 2023	Downgrade	MMaxim Group	Buy → Hold
Aug 04, 2023	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Aug 04, 2023	Downgrade	PPiper Sandler	Overweight → Neutral	$7 → $2	-86.0%
Mar 09, 2023	Initiated	WWilliam Blair	Outperform	$8	-44.0%
Dec 06, 2022	Downgrade	JJefferies	Buy → Hold
Sep 06, 2022	Initiated	PPiper Sandler	Overweight	$7	-51.0%
Apr 07, 2021	Upgrade	MMaxim Group	Hold → Buy	$18	+26.0%
Dec 22, 2020	Downgrade	MMaxim Group	Buy → Hold
Dec 04, 2020	Downgrade	CChardan Capital Markets	Neutral → Sell	$7.50	-47.5%
Oct 22, 2020	Initiated	RRBC Capital Mkts	Sector Perform	$12	-16.0%
Aug 14, 2020	Reiterated	MMaxim Group	Buy	$16 → $22	+54.0%
May 28, 2020	Reiterated	HH.C. Wainwright	Buy	$14 → $21	+47.0%
Jan 31, 2019	Resumed	HH.C. Wainwright	Buy	$6.50	-54.5%

Nov-01-26 06:46PM	Mesoblast Board Changes (GlobeNewswire)
Oct-29-26 12:42AM	Inside Biotech: Mesoblast surges 24% as Ryoncil sales climb and cash spend falls sharply (Proactive) +17.03%
Oct-28-26 08:19PM	Activity Report for Quarter Ended September 30, 2026 (Appendix 4C) (GlobeNewswire)
Sep-24-26 07:00AM	Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product (GlobeNewswire)
Aug-26-26 08:32PM	Mesoblast Reports Substantial Revenue Growth to US$120M (GlobeNewswire) +7.96%
07:00AM	Loading…
Aug-24-26 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-17-26 10:09AM	Mesoblast shares jump as Phase 3 chronic back pain trial completes patient treatment (InvestorsHub) +9.14%
Aug-16-26 08:35PM	Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire)
Jul-29-26 08:57PM	Mesoblast Reports Ryoncil Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch (GlobeNewswire)
Jul-13-26 08:35PM	Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire) +5.05%
Jul-09-26 08:30PM	Ryoncil Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 (GlobeNewswire)
Jun-30-26 08:38PM	Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs (GlobeNewswire)
Jun-24-26 08:59PM	Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility (GlobeNewswire) -6.75%
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire)
Apr-29-26 08:55PM	Mesoblast Reports Ryoncil Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million (GlobeNewswire)
08:53PM	Loading…
Apr-28-26 08:53PM	Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain (GlobeNewswire)
Apr-14-26 08:10PM	Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products (GlobeNewswire) +7.80%
Apr-10-26 04:09PM	Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy - CORRECTION (GlobeNewswire)
Apr-08-26 09:07AM	Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation (GlobeNewswire)
Apr-07-26 11:35PM	Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy (GlobeNewswire) -7.97%
Apr-06-26 09:03PM	Ryoncil Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter (GlobeNewswire)
Mar-18-26 10:00AM	A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. (PR Newswire)
Mar-17-26 07:19PM	Mesoblast to Host R&D Day on April 8, 2026 (GlobeNewswire)
Mar-11-26 07:21PM	Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast (GlobeNewswire)
Mar-03-26 10:02AM	Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them (PR Newswire)
Feb-27-26 12:07AM	Mesoblast H1 Earnings Call Highlights (MarketBeat) -6.32%
Feb-26-26 07:42PM	Ryoncil Profits Underpinning Substantial Growth Pipeline (GlobeNewswire)
Feb-20-26 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-12-26 08:11AM	Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy (Benzinga) -7.70%
Feb-11-26 06:27PM	High Survival Rates With Ryoncil in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD (GlobeNewswire)
06:54PM	Loading…
Jan-28-26 06:54PM	Ryoncil Net Revenues Increase for the Quarter to US$30M (GlobeNewswire)
Jan-27-26 01:01PM	Mesoblast Says Most Children Survive After Early Use Of FDA-Approved Cell Therapy For Organ Transplant Related Complication (Benzinga)
Jan-26-26 06:45PM	Real-World Commercial Experience with Ryoncil Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment (GlobeNewswire)
Jan-20-26 01:33PM	FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain (Benzinga)
Jan-18-26 07:01PM	FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy (GlobeNewswire)
Jan-09-26 12:34PM	Mesoblast Stock Rises On Strong Year-Over-Year Growth In Ryoncil Sales (Benzinga) +5.49%
Jan-08-26 10:05PM	Markets in a Minute: Mesoblast, Alkane Resources shine (Proactive)
06:46PM	Ryoncil Sales Increase 60% in December Quarter to US$35.1M (GlobeNewswire)
Jan-01-26 06:02PM	Mesoblast Announces Changes to Board of Directors' Leadership Roles (GlobeNewswire)
Dec-29-25 06:57PM	Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line (GlobeNewswire)
Dec-16-25 11:53AM	Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy (PR Newswire)
Dec-15-25 12:35PM	Mesoblast (MESO) Sees Optimism From Analysts (Insider Monkey)
Dec-11-25 06:22PM	Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD (GlobeNewswire)
Dec-03-25 06:10PM	Mesoblast Participation at Piper Sandler Conference (GlobeNewswire)
Nov-24-25 06:39PM	Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil Revenue (GlobeNewswire)
Nov-20-25 06:32PM	Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids (GlobeNewswire) +7.33%
Nov-17-25 01:52AM	James M. O'Brien Appointed Chief Financial Officer at Mesoblast (GlobeNewswire)
Nov-10-25 09:55AM	Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now (Zacks)
Nov-04-25 06:40PM	Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation (GlobeNewswire)
Oct-29-25 12:00PM	All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy (Zacks)
Oct-19-25 07:48PM	Ryoncil Net Revenues Increase 69% in Second Quarter Post Launch (GlobeNewswire)
Oct-16-25 04:33PM	Mesoblast's Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement (Insider Monkey) -5.64%
Oct-06-25 07:24PM	Ryoncil Revenues Increase 66% in Second Quarter Post Launch (GlobeNewswire) -5.92%
Oct-02-25 09:04PM	Ryoncil Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access (GlobeNewswire) +8.17%
Oct-01-25 01:46PM	Mesoblast Limited (MESO)'s Ryoncil Gains U.S.-Origin Status, Avoids Import Tariffs (Insider Monkey)
Sep-26-25 01:49AM	Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs (GlobeNewswire)
Sep-14-25 09:18PM	Successful Commercial Launch of Ryoncil Highlighted at Global Healthcare Conferences (GlobeNewswire)
Sep-03-25 09:47PM	Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes (GlobeNewswire)
Aug-28-25 08:24PM	Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil (GlobeNewswire) -13.29%
Aug-27-25 07:00AM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Aug-17-25 01:51AM	Canaccord Genuity Initiates Coverage of Mesoblast Limited (MESO) with Buy Rating (Insider Monkey)
Jul-28-25 10:08AM	Mesoblast Limited (MESO) Launches First Cell Therapy for Children (Insider Monkey)
Jul-22-25 12:00PM	Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know (Zacks)
Jul-17-25 08:38PM	Successful Commercial Launch of Ryoncil (GlobeNewswire) +8.72% +26.58%
Jun-30-25 08:36PM	Mesoblast and FDA Align on Key Items for Revascor Biologic License Application in Ischemic Heart Failure (GlobeNewswire) +11.29%
Jun-29-25 01:28PM	Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil (Insider Monkey)
Jun-11-25 09:24PM	Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD (GlobeNewswire) -6.61%
May-27-25 09:14AM	Which S&P 500 Move Matters? (Motley Fool)
May-14-25 10:57PM	FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil (GlobeNewswire)
May-05-25 02:44AM	Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials (Seeking Alpha) -6.22%
Apr-29-25 08:53PM	Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 (GlobeNewswire)
Apr-28-25 07:44PM	Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board (GlobeNewswire)
Apr-16-25 09:20PM	Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-03-25 06:58PM	Mesoblast Allogeneic Cell Therapy Products Are Designated 'U.S. Country of Origin' and Not Subject to U.S. Tariffs (GlobeNewswire) -8.88%
Apr-02-25 07:15PM	Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor in Ischemic Heart Failure (GlobeNewswire)
Mar-30-25 07:39PM	First Three Children to Commence Treatment With Ryoncil (GlobeNewswire)
Mar-26-25 08:19PM	Ryoncil is Now Available for Purchase in the United States (GlobeNewswire)
Mar-13-25 07:42PM	Ryoncil Product Information Now Available in All Four Major Drug Pricing Compendia in United States (GlobeNewswire)
Mar-12-25 07:30AM	Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall (GlobeNewswire)
Mar-06-25 06:54PM	Mesoblast Added to S&P/ASX 200 INDEX (GlobeNewswire) -7.69%
Feb-26-25 05:30PM	Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter (GlobeNewswire)
Feb-25-25 06:13PM	Mesoblast Financial Results and Corporate Update Webcast (GlobeNewswire)
Feb-23-25 06:33PM	Dr. Gregory George MD PhD Joins Mesoblast Board (GlobeNewswire)
Feb-19-25 06:00AM	Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now (GlobeNewswire)
Feb-13-25 06:37PM	Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings (GlobeNewswire)
Jan-30-25 07:11PM	Ryoncil Commercial Launch Update and Product Pipeline (GlobeNewswire)
06:20PM	Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 (GlobeNewswire)
Dec-19-24 04:21PM	Top-Notch Biotech Mesoblast Skyrockets On Immune Condition Approval (Investor's Business Daily) +36.82% -12.71%
Dec-18-24 07:08PM	Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy (GlobeNewswire)
07:30AM	Mesoblast to be Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-05-24 06:29AM	Mesoblasts Revascor Therapy Shows Promise in Heart Failure (TipRanks)
Dec-04-24 06:32PM	FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease (GlobeNewswire)
Dec-02-24 06:20PM	Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation (GlobeNewswire)
Nov-14-24 06:37AM	Mesoblast Issues 2 Million Warrants for Strategic Flexibility (TipRanks)
Oct-30-24 07:11PM	Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 (GlobeNewswire)
Oct-19-24 06:30AM	Mesoblast Advances Cellular Medicines Amid FDA Hopes (TipRanks)
Sep-29-24 08:55PM	Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch (GlobeNewswire)
Aug-31-24 05:14PM	10 Best Australian Stocks To Buy According to Hedge Funds (Insider Monkey)
Aug-28-24 07:27PM	Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
George Gregory	Director	Apr 04 '26	Buy	1.42	4,000,000	5,680,000	12,000,000	Apr 13 07:19 AM
George Gregory	Director	Apr 10 '26	Buy	1.48	2,324,072	3,439,627	8,324,072	Apr 13 07:19 AM
George Gregory	Director	Apr 09 '26	Buy	1.44	1,586,890	2,277,350	13,586,890	Apr 13 07:19 AM
George Gregory	Director	Apr 09 '26	Buy	8.59	1,981,890	17,015,467	13,586,890	Apr 10 07:27 PM
George Gregory	Director	Apr 04 '26	Buy	1.42	4,000,000	5,680,000	12,000,000	Apr 10 07:27 PM
George Gregory	Director	Apr 10 '26	Buy	1.48	2,324,072	3,439,627	8,324,072	Apr 10 07:27 PM

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

FACRADr. Silviu Itescu FACP

Chief Medical Officer & Executive DirectorDr. Eric A. Rose M.D.

Global Head of Corporate Communications & Joint Company SecretaryMr. Paul Hughes BPHARM

Head of Human ResourcesMr. Anthony Wheal

Ph.D.Dr. Paul J. Simmons BSc

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MESO

Mesoblast Ltd ADR

Upgrade your Finviz experience